American researchers used fat-based nanoparticles to deliver gene therapy to muscle tissue and achieved remarkable progress in regenerating a missing muscle protein. The results of the study are seen as a potential breakthrough for new treatment options for hereditary muscular dystrophies.
The study employed CRISPR technology as the gene editing tool. Researchers also confirmed the treatment outcomes using advanced imaging techniques.
Targeted Disease Type
The research focused on LGMD R7, a rare form of limb-girdle muscular dystrophy. This disease is associated with the loss of the telitin protein, which is essential for the durability of muscle fibers.
Fat-based nanoparticles helped deliver gene editing tools to muscle cells, aiding the regeneration of the missing protein. The study reported an increase of up to 40% in protein production.
Effect Extended Beyond Injection Site
Researchers explained that the effect was not limited to the muscle area where the treatment was administered but also spread to surrounding muscles. This finding suggests a broader potential impact beyond a single localized point.
Experts note that this strengthens the possibility of developing more effective treatments in the future. However, the study does not represent a definitive cure for hereditary muscular dystrophy; at this stage, the finding stands as a promising step at the laboratory and experimental level.
A New Step in the Search for Lasting Treatment
Limb-girdle muscular dystrophy is among rare diseases caused by mutations in more than 30 genes. The disease leads to progressive weakness in shoulder and hip muscles and causes movement limitations in advanced stages.
The limited existing treatment options make scientific advances in this field even more critical. This new finding is considered one of the studies demonstrating that gene therapy can be delivered more precisely to target muscle diseases.
